Eli Lilly: Alzheimer's drug approved in Japan

(CercleFinance.com) - Eli Lilly announces that the Japanese Ministry of Health has approved its Kisunla for adults with early symptomatic Alzheimer's disease, making Japan the second major market in which Kisunla has been approved, after its go-ahead in the US.


Targeted patients include those with mild cognitive impairment, as well as those with the mild dementia stage of Alzheimer's disease, with confirmed amyloid pathology.

The laboratory points out that its Kisunla demonstrated highly significant results in these patients, considerably slowing cognitive and functional decline, in its TRAILBLAZER-ALZ 2 phase III study, which included Japanese participants.

In Japan, by 2030, the number of dementia patients is estimated to exceed five million, and Alzheimer's disease is the most common cause of dementia, accounting for over 67% of cases, it says.


Copyright (c) 2024 CercleFinance.com. All rights reserved.